Mild Traumatic Brain Injury Treatment Market, By Device Type (Imaging Devices (Computed Tomography Devices, Magnetic Resonance Imaging, X-Ray, and Others), Clinical Examination Devices, and Monitoring Devices (Invasive Monitoring Devices and Non-Invasive Monitoring Devices)), By Technique (Intracranial Pressure Monitoring (ICP) and Partial Pressure of Oxygen in Brain Tissue (pBrO2)), By End-Users (Hospitals, Diagnostic Imaging Centers, and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2032

Report Code: PMI265619 | Publish Date: January 2024 | No. of Pages: 186

Global Mild Traumatic Brain Injury Overview

Mild Traumatic Brain Injury also called as concussion where an injury to the brain caused from externally inflicted trauma which causes damage to the blood vessels and brain cells. The symptoms includes, any loss of memory for events before or after an accident, loos of consciousness, and others.

Global Mild Traumatic Brain Injury Drivers & Restraints

Drivers

Restrains

Rising number of road accidents across globe

High costs

Growing geriatric population

 

Increased number of clinical trials worldwide in order to develop effective therapies for TBI

 

New launched product and increased product approval

 

Global Mild Traumatic Brain Injury Segmentations & Regional Insights

The target market is segmented based on Device Type, Technique, End-Users, and Region.

Device Type Insight

On the basis of Device Type, the target market is segmented into Imaging Devices (Computed Tomography Devices, Magnetic Resonance Imaging, X-Ray, and Others), Clinical Examination Devices, and Monitoring Devices (Invasive Monitoring Devices and Non-Invasive Monitoring Devices.

Technique Insight

On the basis of Technique, the target market is segmented into Intracranial Pressure Monitoring (ICP) and Partial Pressure of Oxygen in Brain Tissue (pBrO2).

End-Users Insight

On the basis of End-Users, the target market is segmented into Hospitals, Diagnostic Imaging Centers, and Others.

Regional Insights:

On region the target market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

North America market is estimated to witness a significantly high revenue share over the forecast period.     

  • Rising prevalence of traumatic brain injury diseases.
  • Continuous technological development.
  • Presence of major players.
  • Increased number of product approvals.
  • Well-developed healthcare infrastructure.

Asia Pacific market is estimated to witness a fastest revenue share over the forecast period.      

  • Rising awareness among patients regarding mild traumatic brain injury treatment.
  • Improved healthcare infrastructure.
  • Growing number of players operating in medical industry to develop lower costs and improve mild traumatic brain injury treatment reliability in expanding markets such as India and China.

Recent Development:

             The New Launched Product News,

  • In March 2023, Abbott received U.S. FDA (Food and Drug Administration) clearance for its first commercially available lab-based blood test to detect concussion also called as mild traumatic brain injury (TBI). The test “i-STAT TBI” which runs on Abbott’s Alinity i laboratory instrument provides clinicians to quickly access individuals with mild TBIs. The test is widely available in hospitals at United States.

 

Report Scope:

Attribute

Details

Base year for estimation

2022

Forecast period

2022 – 2032

Market representation

Revenue in USD Billion & CAGR from 2022 to 2032

Market Segmentation

By Device Type - Imaging Devices (Computed Tomography Devices, Magnetic Resonance Imaging, X-Ray, and Others), Clinical Examination Devices, and Monitoring Devices (Invasive Monitoring Devices and Non-Invasive Monitoring Devices

By Technique - Intracranial Pressure Monitoring (ICP) and Partial Pressure of Oxygen in Brain Tissue (pBrO2).

By End-Users - Hospitals, Diagnostic Imaging Centers, and Others

Regional scope

North America - U.S., Canada

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2022 to 2032.

Few Other Promising Reports:

Global Mild Traumatic Brain Injury Competitive Landscape & Key Players

The key players operating the target market includes, TEVA Pharmaceutical Industries Ltd., Neuren Pharmaceuticals Ltd., Medtronic plc., NeuroScience Pharmaceuticals, Tenax Therapeutics, Inc., Vasopharm GmbH, Amarantus Bio Science Holdings Inc., Silver Creek Pharmaceuticals, Inc., Stemedica Cell Technologies, Inc., Banayan Biomarkers, Inc.

FAQs

The growing adoption of innovative technology and new areas of research will potentially change the TBI management that includes, treatment techniques, biomarkers and medications which in turn, is expected to fruitful the demand for target market growth.

By region, the target market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The North America market is estimated to witness a significantly high revenue share over the forecast period.

The key players operating the target market includes, TEVA Pharmaceutical Industries Ltd., Neuren Pharmaceuticals Ltd., Medtronic plc., NeuroScience Pharmaceuticals, Tenax Therapeutics, Inc., Vasopharm GmbH, Amarantus Bio Science Holdings Inc., Silver Creek Pharmaceuticals, Inc., Stemedica Cell Technologies, Inc., Banayan Biomarkers, Inc.